Saniona AB (0RQJ) fair value: what the stock is really worth
As of Sep 29, 2026: fair value of Saniona AB SEK 1.69, price SEK 9.65, upside -82.5%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Saniona AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels.
Show more
Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy that has completed Phase 2 clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor; SAN903, a novel medicine based on inhibition of the calcium-activated potassium ion channel, which has completed preclinical development for the treatment of inflammatory bowel disease; SAN2219, a subtype selective positive allosteric modulator of GABAA a2- a3- and a5 that is in preclinical stage for treatment of acute repetitive seizures; SAN2355 to treat resistant focal onset seizures; SAN2668, a therapy for severe pediatric epilepsies, including developmental epileptic encephalopathies; and SAN2465, a negative allosteric modulator to treat major depressive disorder. It has research and collaboration agreements with Boehringer Ingelheim International GmbH to research, develop, manufacture, and commercialize therapeutics; license agreement with Productos Medix, S.A. de C.V. develop and commercialize tesofensine and/or Tesomet; research services agreement and a collaboration agreement with Cephagenix ApS to identify and develop novel migraine treatments; and research collaboration with AstronauTx to research, develop, manufacture, and commercialize therapeutics for Alzheimer's disease. The company was founded in 2011 and is headquartered in Glostrup, Denmark.
Stock analysis
Saniona AB (0RQJ) currently trades at kr 9.65, while our model-based Fair Value estimate is kr 1.69, 82.5% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.
Scenario range: kr 1.12 (bear) to kr 2.11 (bull), the price of kr 9.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Saniona AB reported revenue of 8.2M SEK in FY2020 versus 74.9M SEK in FY2016, a compound −42.5%/yr. Reported net income was −73.4M SEK in FY2020.
Key figures
Market cap 243M SEK (≈ $24.2M) · P/S ratio 0.57 · EPS (TTM) kr −7.39 · Net margin 51.1% · Return on equity 52.2% · Return on assets (EBIT) −58.3% · Operating margin −1,185% · Revenue growth (YoY) −52.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 65% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −82%, 0RQJ screens richer than that median.
Fair Value models
Bear kr 1.12Fair Value kr 1.69Bull kr 2.11
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.60/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
5.5% (2016) → −1,293.6% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 5/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score45 · Above median
Fair Value upside−85.7% · Bottom 25%
Profitability
Return on equity (TTM)52.2% · Top 25%
Return on assets30.1% · Top 25%
Net margin (TTM)51.1% · Top 25%
Growth and dividend
Revenue growth−52.2% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Saniona AB Fair Value". https://www.fairvalue-calculator.com/stock/0RQJ
Frequently asked questions
Is Saniona AB (0RQJ) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 1.69 versus a price of kr 9.65, about −82% upside (overvalued).
What is the fair value of 0RQJ?
Our model-based fair value for Saniona AB is kr 1.69 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 9.65.
What is the quality score of 0RQJ?
Saniona AB has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Saniona AB (0RQJ)?
Our model-based price target is the fair value of kr 1.69 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario kr 1.12, optimistic scenario kr 2.11. It is a calculation from audited fundamentals, not an analyst target.
What is the Saniona AB stock forecast for 2026?
Our models put fair value at kr 1.69, about −82% upside versus a price of kr 9.65 (overvalued). Cautious scenario kr 1.12, optimistic scenario kr 2.11. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Saniona AB (0RQJ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Saniona AB it is kr 1.69 per share (as of Sep 24, 2026), against a price of kr 9.65. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Saniona AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0RQJ trades above its calculated fair value: price kr 9.65, fair value kr 1.69, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0RQJ?
No. The price is what the market pays today (kr 9.65); the fair value is what the company's own numbers justify (kr 1.69). For Saniona AB the two are kr 7.96 per share apart. That gap is exactly why we show both numbers side by side.
How much is Saniona AB worth?
The market values Saniona AB at about 243M SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 9.65; our models calculate a fair value of kr 1.69 per share.
What do the bullish and bearish scenarios say about 0RQJ?
Our models span a range for Saniona AB: cautious scenario kr 1.12, base kr 1.69, optimistic kr 2.11 per share (as of Sep 24, 2026, price kr 9.65). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Saniona AB (0RQJ)?
Balance-sheet figures for Saniona AB (as of Sep 24, 2026): return on equity 52.2%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 0RQJ from its 52-week high?
Saniona AB trades at kr 9.65, about 65% below its 52-week high of kr 27.68 and 1% above the low of kr 9.53 (as of Sep 29, 2026). Distance from the high says nothing about value: that is what the fair value of kr 1.69 is for.
Which stocks are comparable to Saniona AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Saniona AB stock attractive at the current price?
The data as of Sep 24, 2026: price kr 9.65, calculated fair value kr 1.69 (−82%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0RQJ calculated?
We run Saniona AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 1.69, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Saniona AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Saniona AB (0RQJ)?
The closing price on Sep 29, 2026 was kr 9.65. Our model-based fair value is kr 1.69, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Saniona AB right now?
The price sits above even our optimistic bull case (kr 2.11). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 1.12 to kr 2.11) leaves room in how you read the outcome.
Key figures of Saniona AB
How large is the market capitalisation of Saniona AB (0RQJ)?
The market capitalisation of Saniona AB is 243M SEK (≈ $24.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Saniona AB (0RQJ)?
The price-to-sales ratio of Saniona AB is 0.57 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Saniona AB (0RQJ)?
Earnings per share at Saniona AB are kr −7.39. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Saniona AB (0RQJ)?
The net margin of Saniona AB is 51.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Saniona AB (0RQJ)?
The return on equity (ROE) of Saniona AB is 52.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Saniona AB (0RQJ)?
On an EBIT basis the return on assets of Saniona AB is −58.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Saniona AB (0RQJ)?
The operating margin of Saniona AB is −1,185% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Saniona AB (0RQJ)?
Revenue at Saniona AB is growing −52.2% versus a year earlier (3y avg −26.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed
Watch Saniona AB in the live analysis
One click puts Saniona AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
